Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Bortezomib and dexamethasone with cyclophosphamide (CyBorD) or melphalan (BMDex) are commonly used primary treatments for light-chain (AL) amyloidosis, but limited data exist on bortezomib with immunomodulatory drug combinations. We report our experience with primary therapy with a bortezomib, lenal...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Kastritis, Efstathios, Dialoupi, Ioanna, Gavriatopoulou, Maria, Roussou, Maria, Kanellias, Nikolaos, Fotiou, Despina, Ntanasis-Stathopoulos, Ioannis, Papadopoulou, Elektra, Ziogas, Dimitrios C., Stamatelopoulos, Kimon, Manios, Efstathios, Ntalianis, Argyrios, Eleutherakis-Papaiakovou, Evangelos, Papanikolaou, Asimina, Migkou, Magdalini, Papanota, Aristea-Maria, Gakiopoulou, Harikleia, Psimenou, Erasmia, Tselegkidi, Maria Irini, Tsitsilonis, Ourania, Kostopoulos, Ioannis, Terpos, Evangelos, Dimopoulos, Meletios A.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2019
Subjects:
Lymphoid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849948/
https://ncbi.nlm.nih.gov/pubmed/31648323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000147
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items